Jan Beumer, PharmD, PhD, DABT has been re-elected NCI IDSC co-chair by and from among his IDSC peers. The National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC) provides NCI with broad external scientific and clinical input on the design and prioritization of phase I and phase II trials with agents for which Cancer Therapy Evaluation Program (CTEP) holds an Investigational New Drug (IND) application. The IDSC aims to increase the predictive value of early phase trials, resulting in the design of more successful phase III trials.

Dr. Beumer’s two-year term begins on 1/1/2021. Additionally, he co-chairs the IDSC Pharmacology Task Force and is a member of the IDSC Clinical Trial Design Task Force and the IDSC coordination team.

Comments are closed.